THE FIGHT against COVID-19 has reached a turning point with the approval of two oral antiviral treatments, molnupiravir and a combination of nirmatrelvir and ritonavir (available under the brand name Paxlovid). With the promise to reduce the risk of hospitalisations and deaths, these pills could well help manage the pandemic, but they cannot end it— not alone.
Clinical-trial data shows that molnupiravir, developed by the USbased pharmaceutical firm Merck and biotechnology company Ridgeback Biotherapeutics, cuts the risk of hospitalisation or death by 30-50 per cent. Paxlovid, developed by another pharmaceutical and biotechnology giant Pfizer, cuts the risk by 88 per cent. Since the UK regulators approved molnupiravir in November and Paxlovid in December last year, and the US regulators granted emergency use authorisations (EUA) for both drugs in December, several other countries, struggling to contain rising cases due to the Omicron variant of the novel coronavirus (SARS-COV-2), have followed suit. Since the pills are in short supply, wealthy countries have already locked in huge contracts, as they did with COVID-19 vaccines, and the others are negotiating with the drug makers to manufacture generic versions. The UN Medicines Patent Pool that aims to improve access to medication has freed molnupiravir's patent for lowand middle-income countries.
But there are some who are treading cautiously. Till the third week of January 2022, India had not given approval to the use of Paxlovid. Though an EUA was granted for molnupiravir, it was not made part of the national COVID-19 treatment protocol. Several companies in the country have, however, started making the drug available for anywhere between ₹1,600 and ₹3,000 per course.
Diese Geschichte stammt aus der February 01, 2022-Ausgabe von Down To Earth.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der February 01, 2022-Ausgabe von Down To Earth.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.